NA
MURA

Nordwand Advisors’s Mural Oncology MURA Stock Holding History

Nordwand Advisors’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$3.13K – 130
2024
Q3 		$3.13K Buy
+1,000
New +$3.26K ﹤0.01% 108

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Nordwand Advisors's MURA Position: Q4 2024 in Review

Nordwand Advisors sold out of Mural Oncology (MURA) in Q4 2024, closing a stake of 1,000 shares — an estimated $3.13K sold.

Nordwand Advisors first reported a position in MURA in Q3 2024 and held it in 1 quarter. The position peaked at $3.13K in Q3 2024. 76 funds tracked by Wall St. Rank hold MURA as of Q4 2024.

  • Nordwand Advisors reported no remaining Mural Oncology position as of Q4 2024 after selling out during the quarter.
  • Nordwand Advisors sold 1,000 Mural Oncology shares in Q4 2024, an estimated $3.13K.
  • Nordwand Advisors first reported a position in Mural Oncology in Q3 2024 and held it in 1 quarter.
  • Nordwand Advisors's Mural Oncology position peaked at $3.13K in Q3 2024.
  • 76 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2024.

Based on Nordwand Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.